reported.
1,2 Although a PCR-determined monoclonal rearrangement of IgH in B cell lymphomas is strong evidence for the diagnosis of PIOL, there has been no other report of this fi nding. Only a few malignant cells were present in the vitreous cavity, and they were poorly preserved in the cases reported heretofore, so it was diffi cult to determine B cell monoclonality from both PIOL and PCNSL. It was diffi cult in our case, as well.
In all these cases, including ours, the PCNSL was detected fi rst by brain biopsy and treated with radiation of the brain and systemic chemotherapy. In spite of the systemic chemotherapy, a PIOL developed later. We suggest that the tumor cells probably escaped the initial treatment because of their virulence, or the failure of systemic chemotherapy to contact the malignant cells due to the blood-ocular barrier. However, mild vitreous opacity existed prior to PCNSL in our case. Interestingly, bilateral identical monoclonality in PIOL has been detected without PCNSL involvement. 5 This may indicate that tumor cells may have already have been present in the eye in this reported case. 5 The fi nding of an identical IgH gene rearrangement supports the idea that the PCNSL and PIOL in our patient resulted from a dissemination of the same neoplastic clone rather than a simultaneous neoplastic formation of multiple B cell clones.
Primary Conjunctival Follicular
Lymphoma Treated with the Anti-CD20 Antibody Rituximab and Low-Dose Involved-Field Radiotherapy Follicular lymphoma (FL) originating in the ocular adnexa is rarely reported, and curative radiotherapy for it is still questionable. Herein, we report a case of primary FL treated with rituximab, a monoclonal antibody therapy, followed by low-dose involved-fi eld radiotherapy (LD-IF-RT).
Case Report
A 67-year-old Japanese man was referred with a 2-month history of a progressive tumor in the conjunctiva of his right eye (Fig. 1a, b) . A tumor sample was obtained by incisional biopsy. By histopathological analysis, it was found to consist of proliferated medium-sized atypical centrocytic lymphoid cells, forming a follicular nodule (Fig. 2a, c) . Large centroblastic cells were very few in the nodule (Fig. 2c) . The lymphoid cells showed positive immunoreactivity for CD20, CD79α, CD10, bcl-6 (Fig. 2d) , and bcl-2 (Fig. 2e) . Polymerase chain reaction (PCR) using the tumor DNA detected a fusion product of the major breakpoint region of the bcl-2 gene and IgH J region 1 (Fig. 2f) . Based on these fi ndings, the lesion was diagnosed as a follicular lymphoma (FL) grade 1, according to the World Health Organization classifi cation (2001). 2 Consecutive general examinations (including whole-body computed tomography, and Ga-scintigraphy) did not detect any other primary or metastatic lesions. One month after his initial visit, a similar lesion appeared in the conjunctiva of the left eye of the patient (Fig. 1c) , and also proved to be an FL grade 1 by an additional biopsy (Fig.  2b) and immunohistochemical studies.
The patient underwent anti-CD20 antibody therapy (rituximab, 375 mg/m 2 intravenously once weekly for 4 weeks), and the lesions decreased in size gradually. Subsequently, LD-IF-RT with a regimen of 2 days of 2 Gy by X-ray (4 Gy total) for both orbital regions was performed. The conjunctival lesions in both eyes diminished approximately 1 month after the LD-IF-RT (Fig. 1d) , and no local recurrence or metastasis was observed during the following 22 months.
Comments
Primary conjunctival FL is very rare. Reverse transcriptase PCR was useful to detect a t(14;18) (q32;q21) translocation from a very small sample of the conjunctival lesion. Until several years ago, the management of FL was basically palliative. Recently, the effi cacy of rituximab therapy for FL has been evaluated. In a few clinical trials using rituximab alone for untreated FL, response rates ranged between 61% and 80%. 3 So far, only one case of conjunctival FL treated with rituximab alone has been reported. 4 However, the evidence for diagnosis was not shown, and the follow-up period was only 5 months. 4 Generally, the common side effects of rituximab are not severe, and include fever, chills, and nausea. No side effect of rituximab was observed in this case.
Radiotherapy with curative intent for early-stage FL is still questionable because of the recurrence rate of approximately 50% and the treatment side effects. LD-IF-RT (2 × 2 Gy regimen) was initially applied to treat recurrences of advanced FL. Recent studies showed high response rates (>80%) in indolent lymphoma patients. 5 We combined rituximab therapy and LD-IF-RT, since it is too early to evaluate the effi cacy of each of them independently on survival. Minimizing radiation-induced disorders of eyes, that is, cataract, was also another reason to select LD-IF-RT. As it happens, this therapeutic idea is supported by a recent study showing that pretreatment with rituximab enhances the radiosensitivity of non-Hodgkin's lymphoma cells. 6 In conclusion, for early stage conjunctival FL, the combination of anti-CD20 antibody therapy and LD-IF-RT may be an alternative therapy.
